Verantos enables real-world evidence that is as advanced as your therapy
Today’s therapeutics are often indicated for disease subtypes (e.g. severe asthma, moderate-to-severe ulcerative colitis, chronic migraine). For these therapies, RWD must include information on disease subtype. This level of granularity is only available from unstructured EHR data.
Some critical variables, such as findings like ejection fraction in heart failure and mucosal bleeding in inflammatory bowel disease, do not have a code. To capture these findings at scale, they must be extracted from unstructured EHR data using artificial intelligence.
Having the richest dataset is moot, however, if the data are not reliable. Verantos is the only company that measures the accuracy, completeness, and traceability of its RWD. High-quality RWD is required to generate high-validity RWE. Verantos publishes peer-reviewed manuscripts validating the outputs of our technology.
Products
Pragmatic Registry
Pragmatic Registry enables life sciences companies to subscribe to indication-specific data sets that represent patient cohorts generated using deep phenotyping and linkage. Measurable industry-leading data reliability enabling high-validity evidence generation facilitates clinical assertions to support clinician, payer, and regulator decision-making.
Observational Research
Observational Research generates high-validity real-world evidence (RWE) to power life sciences companies’ observational studies. These longitudinal studies are executed using deep phenotyping to support difficult inclusion and exclusion criteria, endpoints, and outcomes.
Recent validation
These recent publications validate the outputs of our technology.
Heart failure
Migraine
Severe asthma
The Verantos advantage
Market access
- More credible evidence to help payers and health technology assessment (HTA) bodies understand the value of today’s therapies
- High-reliability RWD your teams can use to generate high-validity real-world evidence, which is necessary for credibility in conversations with payers
- Rapid time-to-value, shortening the delay in moving from UM-controlled access to preferred brand tier
Pharmacovigilance
- Pragmatic registries from high-accuracy RWD reduce false positives in potential safety signals
- Better safety contextualization of patients experiencing adverse reactions
- Earlier detection of real-world safety signals from more representative populations to reduce risk of onerous post-marketing studies
Clinical development
- Complete view of the patient journey without the overhead of consented registries
- Patients from community health systems and academic medical centers and provide more representative outcomes
- Larger sample sizes with more granular phenotyping